CAR T cells: Building on the CD19 paradigm

• Published in: European journal of immunology Vol. 51; no. 9; pp. 2151 - 2163
• Main Authors: Globerson Levin, Anat, Rivière, Isabelle, Eshhar, Zelig, Sadelain, Michel
• Format: Journal Article
• Language: English
• Published: Weinheim Wiley Subscription Services, Inc 01.09.2021
• Subjects: Antigens; Autoimmunity; Cancer immunotherapy; CD19; CD19 antigen; Cell surface; Chimeric antigen receptor (CAR) T cell; Chimeric antigen receptors; Cytotoxicity; Genome editing; Genomes; Immunotherapy; Lymphocytes; Lymphocytes T; Macrophages; Major histocompatibility complex; Natural killer cells; Pluripotency; Senescence; Solid tumors; Stem cells; Tumor immunology; Variable region
• ISSN: 0014-2980; 1521-4141; 1521-4141
• DOI: 10.1002/eji.202049064

Spearheaded by the therapeutic use of chimeric antigen receptors (CARs) targeting CD19, synthetic immunology has entered the clinical arena. CARs are recombinant receptors for antigen that engage cell surface molecules through the variable region of an antibody and signal through arrayed T‐cell acti...